ライフサイエンスコーパス: convalescent

1 on), 24% (early convalescent), and 11% (late convalescent).

2 body fluid specimens were also obtained from convalescents.

3 obtained during the acute (within 48 h) and convalescent (4 to 6 weeks postinfection) phases, at whi

4 highest sensitivities in the acute (56%) and convalescent (94%) phases of leptospirosis.

5 The use of convalescent and nursing homes or home health care after

6 Twenty-nine EHF convalescents and 152 HHCs were monitored for up to 21 m

7 d and symptom information was collected from convalescents and their HHCs; other body fluid specimens

8 dividuals, were 13% (incubation), 24% (early convalescent), and 11% (late convalescent).

9 m samples from Nicaragua collected at acute, convalescent, and 12-mo timepoints.

10 ficity of bactericidal antibodies in normal, convalescent, and postvaccination human sera is importan

11 The sensitivities for acute-, convalescent-, and late-phase specimens were 74% (29 of

12 cardiac scar formation was observed only in convalescent animals by transmission electron microscopy

13 Convalescent animals which recovered from exposure to vi

14 Three animals were rescued with antibiotics (convalescent animals).

15 Across cohorts, convalescent anti-Hla titers correlated with protection

16 Convalescent antibodies from individuals who had recover

17 We used human convalescent antibody (Ab) to clone a gene that encoded

18 s competed extensively with polyclonal human convalescent antibody (PcAb); however, combinations of a

19 Bovine convalescent antisera (obtained from contemporary natura

20 However, despite strong cross-reactivity of convalescent antisera between related arenavirus species

21 sittaci DNA was differentially screened with convalescent antisera from infected guinea pigs and anti

22 Western blot analysis with convalescent antisera identified several low-calcium-res

23 rface-exposed protein that reacts with human convalescent antisera.

24 Herein we demonstrate that convalescent B1b cell-derived IgM recognizes complement

25 strong anamnestic response was observed when convalescent baboons were infected 6 months following re

26 f Salmonella serovar Pullorum persistence in convalescent birds are not known, and the mechanisms of

27 ample collected at enrollment, and 184 had a convalescent blood sample.

28 or HGE, whereas serum IFA assays of acute or convalescent blood samples detected antibodies against E

29 Among 187 cases with acute and convalescent blood samples, 85 (45%) showed evidence of

30 ) were studied prospectively to determine if convalescent body fluids contain Ebola virus and if seco

31 B1b cells from convalescent but not naive mice confer long-lasting immu

32 d antibody against the R6 protein present in convalescent, but not acute, serum samples.

33 Forty-six percent of acute, 27% of convalescent case, and 11% of control stool samples test

34 tion is that it persists for long periods in convalescent chicks in the absence of clinical disease.

35 Serum samples from convalescent children were obtained and the isolate was

36 assay using sera from vaccinated adults and convalescent children.

37 vidual, these patients experienced a stable, convalescent clinical course, remained free of uremic sy

38 , 59 of which had higher immunoreactivity in convalescent compared with acute-stage or healthy contro

39 g an Ehrlichia canis expression library with convalescent dog sera, which resulted in three positive

40 rol and Prevention to include hospital-based convalescent donations and transfusions.

41 dies (mAbs) from the peripheral B cells of a convalescent donor who survived the 2014 EBOV Zaire outb

42 each unit of plasma obtained from a separate convalescent donor.

43 All convalescent E70/43-infected animals survived infection

44 A cohort of convalescent Ebola hemorrhagic fever (EHF) patients and

45 8% of angioplasties, the delay exceeded 1 h: convalescent EF 57.3%.

46 on was similar in both treatment groups, but convalescent ejection fraction (EF) was highest with a p

47 Immunoblotting with convalescent equine sera revealed that some proteins exh

48 Convalescent excretion of Campylobacter after a diarrhea

49 These experiments demonstrate that convalescent FFP shows promise as a postexposure HPS pro

50 -related hospital admission and at a 3-month convalescent follow-up visit.

51 ents with acute hepatitis B, and 12 patients convalescent from acute hepatitis B, were stimulated wit

52 quired for B. parapertussis to colonize mice convalescent from B. pertussis infection.

53 convalescent from HGE, and sera from horses convalescent from HGE and E. equi infection.

54 munized with the HGE agent, sera from humans convalescent from HGE, and sera from horses convalescent

55 Marmosets and chimpanzees convalescent from infection with the AGM-27 strain of HA

56 ated and convalescent subjects; however, the convalescent group had higher titers in the PBMC assay.

57 aluated in neutralizing antibody assays with convalescent H3N2 ferret serum, yielding a neutralizatio

58 open to the influx of potentially infectious convalescents (hereafter referred to as "open units," an

59 Sera from naturally infected convalescent horses had only limited sAg-neutralizing ac

60 whole group A streptococci and in polyclonal convalescent human antisera from children that had recov

61 xclusively dominant epitope expressed in the convalescent human antisera was the doubly branched exte

62 h influenza pneumonia who received influenza-convalescent human blood products may have experienced a

63 a era reported that transfusion of influenza-convalescent human blood products reduced mortality in p

64 ideal, but this is dependent upon serum from convalescent human donors, which is in limited supply.

65 Convalescent human H5N1 plasma could be an effective, ti

66 roach is passive administration of sera from convalescent human MERS patients or other animals to exp

67 s for H5N1 influenza are unsatisfactory, and convalescent human plasma containing H5N1 antibodies cou

68 rom mice infected with strain H10407 or with convalescent human sera obtained following natural ETEC

69 Enzyme-linked immunosorbent assay (ELISA) of convalescent human serum samples revealed that proteins

70 panel included a dilution series of an early convalescent human serum, known-positive sera (undiluted

71 Passively transferred serum from convalescent IgA(-/-) mice was not as effective as serum

72 However, naive and convalescent IgA(-/-) mice were defective in reducing th

73 Here, we determined that convalescent immune plasma from a horse persistently inf

74 cells with RV-sIg in children with acute and convalescent infection.

75 edding for 4-5 days and significant rises in convalescent influenza antibody titers.

76 ed whole blood of 12 patients with acute and convalescent Kawasaki disease were analyzed by sequencin

77 atient with fatal acute KS and screened with convalescent KS serum followed by anti-human Ig.

78 Convalescent levels for 2 of 4 serotypes were greater in

79 ls were treated with homologous ZEBOV-Makona convalescent macaque sera, 3 animals were treated in par

80 l with heterologous Sudan ebolavirus (SEBOV) convalescent macaque sera, and 2 animals served as posit

81 elta2(+) T cell absolute counts at acute and convalescent malaria timepoints (n = 43), and Vdelta2(+)

82 sion of EHF was found, although the semen of convalescents may be infectious.

83 Serum from convalescent MERS patients may provide some benefit but

84 ium after cell therapy in a porcine model of convalescent MI.

85 ium after cell therapy in a porcine model of convalescent MI.

86 a nasal Ab titer comparable to that seen in convalescent mice eliminated nasal viral shedding.

87 Consistent with this, we found that convalescent mice rapidly cleared the bacteria after rei

88 h a significant reduction in the capacity of convalescent mice to mount an enhanced recall response t

89 ng immunity against the modified strain, and convalescent mice were protected from both subcutaneous

90 These convalescent mice were then challenged with homologous b

91 nd proliferated rapidly after rechallenge of convalescent mice.

92 to be critically important for survival in a convalescent model of SchuS4 infection, IL-17 neutraliza

93 ivery of cardiospheres in a porcine model of convalescent myocardial infarction.

94 Acute and convalescent nasopharyngeal swabs and sera were obtained

95 ed in the myocardium of both acutely ill and convalescent NHPs.

96 eumococcal infection in both acutely ill and convalescent NHPs.

97 the addition of gamma-irradiated autologous convalescent or allogeneic PBMC.

98 ly localized or early disseminated disease), convalescent, or late disease phase.

99 e uncomplicated P. falciparum, P. vivax, and convalescent P. falciparum infections.

100 identified in immunoproteomic studies using convalescent patient sera, is required for efficient acc

101 from a number of healthy donors and from one convalescent patient.

102 n 5 (20%) of 25 urine samples collected from convalescent patients 573-2452 days (1.6-6.7 years) afte

103 sistence was examined in body fluids from 12 convalescent patients by virus isolation and reverse tra

104 epitopes, recognized by acutely infected or convalescent patients in the context of a wide range of

105 ntibody, designated CT149, was isolated from convalescent patients infected with pandemic H1N1 in 200

106 n from fomites in an isolation ward and from convalescent patients is low when currently recommended

107 ffectiveness of whole blood transfusion from convalescent patients on survival.

108 urvival benefit of transfusion of blood from convalescent patients was evident after adjusting for ag

109 ntibodies were isolated from three different convalescent patients with distinct histories of DENV in

110 hat were isolated from B-cell populations of convalescent patients.

111 cit T-cell responses in infected mice and in convalescent patients.

112 or a much shorter period among the surviving convalescent patients.

113 mor, semen, and breast milk from infected or convalescent patients.

114 h, reflect two separate hospitalizations and convalescent periods.

115 illance, interviews, examinations of ill and convalescent persons, medical chart reviews, and laborat

116 from both eyes of these patients at the late convalescent phase (30 days post-illness).

117 Detection of NSVT during the convalescent phase (n=428/1991; 21.5%) was also associat

118 ts undergoing cardiac catheterization in the convalescent phase after Fontan operations.

119 KV-reactive T cells continues to rise in the convalescent phase in DENV-naive donors but declines in

120 iography compared with no angiography in the convalescent phase of acute myocardial infarction, but s

121 A screening from 68 men in Guinea during the convalescent phase of EBOV infection.

122 d not return to the baseline even during the convalescent phase of the infection.

123 to test acute, convalescent phase, and post-convalescent phase serum/plasma samples from reverse-tra

124 ever, patients with NSVT detected during the convalescent phase were also at a significantly increase

125 tein 1 (NS1) were established to test acute, convalescent phase, and post-convalescent phase serum/pl

126 ed at 1 month after randomization during the convalescent phase.

127 the recombinant gp140, gp200, and p28 in the convalescent phase.

128 ation of TSPyV seroresponses occurred in the convalescent phase.

129 tional capacity to control levels during the convalescent phase.

130 brary of Nine Mile phase I was screened with convalescent-phase antisera from mice.

131 Virus neutralization assays using convalescent-phase antisera raised against the parental

132 o an increase in the index of avidity to the convalescent-phase antisera.

133 oblotted, and probed with hyperimmune and/or convalescent-phase antiserum to rapidly identify vaccine

134 holerae proteins were recognized uniquely by convalescent-phase as opposed to acute-phase serum from

135 virus (EBOV) infection after transfusions of convalescent-phase blood during a 1995 outbreak of EBOV

136 lins or monoclonal antibodies, we transfused convalescent-phase blood from EBOV-immune monkeys into n

137 The use of convalescent-phase human plasma is an effective treatmen

138 erential immunoreactivities in acute- versus convalescent-phase human serum samples, we found specifi

139 to animal CoVs and SARS-CoV and SARS patient convalescent-phase or negative sera.

140 Transfer of convalescent-phase or nonneutralizing rotavirus-specific

141 e of GII.4 VLP-HBGA binding was greater with convalescent-phase outbreak sera collected near the time

142 Two-dimensional gels and immunoblots using convalescent-phase patient sera and murine sera revealed

143 y passive hemagglutination in the acute- and convalescent-phase patient sera.

144 combinants are combined, 96.2% (26 of 27) of convalescent-phase patient serum samples and 85.2% (23 o

145 hocytes recovered to almost normal levels in convalescent-phase PBMC from most patients.

146 dominantly exhibited on CD4 T lymphocytes in convalescent-phase PBMC.

147 In infected humans, convalescent-phase plasma containing neutralizing antibo

148 le or of a >/=4-fold rise to >/=1:3,200 in a convalescent-phase sample provided the highest accuracy

149 d the optimal cutoff titers in admission and convalescent-phase samples for scrub typhus indirect imm

150 agellin (FlaB), OspC, and OspA in acute- and convalescent-phase samples from 39 culture-positive pati

151 In both acute- and convalescent-phase samples, cellular immune responses we

152 dian = 6.0) after the onset of symptoms, and convalescent-phase sera (n = 128) were collected >or=15

153 d aa 1 to 213 reacted specifically with SARS convalescent-phase sera but not with negative human sera

154 ole or fractionated bacterial proteomes with convalescent-phase sera can potentially accelerate ident

155 pneumonic plague models, passive transfer of convalescent-phase sera confers protection, as does acti

156 d rise in antibody titer from acute-phase to convalescent-phase sera for LukAB, the most recently des

157 By using convalescent-phase sera from 10 Shigella flexneri-infect

158 Convalescent-phase sera from 33 of 44 patients in the PS

159 epitope were highly reactive with all of the convalescent-phase sera from 40 SARS patients but not wi

160 The recombinant proteins reacted with convalescent-phase sera from dogs and human patients rec

161 In this study, we investigated convalescent-phase sera from H7N7-exposed individuals by

162 Convalescent-phase sera from NV-infected individuals sho

163 ), respectively, by Pepscan analyses against convalescent-phase sera from SARS patients and antisera

164 ts with seven different sera, including five convalescent-phase sera from these patients, one dog ant

165 Convalescent-phase sera from these primed mice conferred

166 mmunosorbent assays (ELISAs) with human HCMV-convalescent-phase sera from unselected donors confirmed

167 rediction model were significantly higher in convalescent-phase sera than in paired acute-phase sera.

168 gic study was conducted on stored acute- and convalescent-phase sera that had been submitted for Rock

169 pment of serological criteria for evaluating convalescent-phase sera that optimize detection of true

170 capsid and reacted with pig hyperimmune and convalescent-phase sera to PEC Cowden in enzyme-linked i

171 The sensitivity for convalescent-phase sera was 93.8% by MAT, 84.4% by DST,

172 In this study, acute- and convalescent-phase sera were evaluated against different

173 erved in 21 of 23 patients (91.3%) from whom convalescent-phase sera were obtained.

174 of human sera, including group C and group B convalescent-phase sera, normal sera with naturally occu

175 When used to examine convalescent-phase sera, the IFA is positive in 93% of b

176 on of 2009 H1N1 virus-specific antibodies in convalescent-phase sera.

177 body titers between collection of acute- and convalescent-phase sera.

178 he carboxyl-terminal half of IpaD with a few convalescent-phase sera.

179 Convalescent-phase serology is impractical, blood cultur

180 acid (CMP-NANA) to increase LPS sialylation, convalescent-phase serum bactericidal titers were decrea

181 Antibody to rDR2/Fic or passively protective convalescent-phase serum blocked IbpA-mediated cytotoxic

182 Convalescent-phase serum collected from a GII.4.2009 out

183 eutralization of GI VLPs was demonstrated by convalescent-phase serum cross-blockade of GI VLP-HBGA i

184 Convalescent-phase serum from a patient with an active G

185 era from infected/vaccinated guinea pigs and convalescent-phase serum from human patients who had rec

186 Convalescent-phase serum from humans following clinical

187 1996 using a large collection of acute- and convalescent-phase serum pairs (n = 298) collected from

188 f these patients without the submission of a convalescent-phase serum sample.

189 sis--specific 31-kD antigen were detected in convalescent-phase serum samples from 11 patients.

190 The geometric mean titers of the acute- and convalescent-phase serum samples measured by IFA were 1:

191 Acute- and convalescent-phase serum samples obtained from 42 patien

192 All nine convalescent-phase serum samples tested had neutralizing

193 ing titer were observed when acute-phase and convalescent-phase serum samples were compared (168 [44%

194 Our findings were validated using a convalescent-phase serum specimen from a patient infecte

195 LD-endemic areas to provide acute- (S1) and convalescent-phase serum specimens (S2).

196 erence-blocking monoclonal antibody F2G5 and convalescent-phase swine sera.

197 samples were obtained at the acute and early convalescent phases from ZIKV-infected patients during t

198 G2 antibodies exclusively in both acute and convalescent phases in most dogs.

199 SVT occurred frequently during the acute and convalescent phases of ACS.

200 ncentrations for incubation, early, and late convalescent phases of infection between people with non

201 vels of parasitemia and during the acute and convalescent phases of the infection.

202 e during relapse and six during asymptomatic convalescent phases).

203 he acute (postinoculation day 3 [PID 3]) and convalescent (PID 28) stages of infection.

204 From the 22 convalescent pigs, significantly more A+ or H+ pigs (66%

205 The clinical evaluation of convalescent plasma (CP) for the treatment of Ebola viru

206 Immunotherapy using infusion of convalescent plasma (or hyperimmune intravenous immunogl

207 small interfering RNA, brincidofovir, and/or convalescent plasma as investigational therapeutics.

208 prioritized the evaluation of treatment with convalescent plasma derived from patients who have recov

209 We evaluated the safety and efficacy of convalescent plasma for the treatment of EVD in Guinea.

210 Using convalescent plasma from DENV- and WNV-infected individu

211 unclear what role the experimental drug and convalescent plasma had in the recovery of these patient

212 Administration of DENV- or WNV-convalescent plasma into ZIKV-susceptible mice resulted

213 or a reduction in mortality, especially when convalescent plasma is administered early after symptom

214 Convalescent plasma may reduce mortality and appears saf

215 adverse reactions associated with the use of convalescent plasma were observed.

216 The transfusion of up to 500 ml of convalescent plasma with unknown levels of neutralizing

217 Administration of convalescent plasma, serum, or hyperimmune immunoglobuli

218 h multiple investigational agents, including convalescent plasma, which limits generalizability of th

219 nsfusions of 200 to 250 ml of ABO-compatible convalescent plasma, with each unit of plasma obtained f

220 investigational therapeutic (TKM-100802) and convalescent plasma.

221 ient with EVD who received brincidofovir and convalescent plasma.

222 diagnosis, the risk of death was 31% in the convalescent-plasma group and 38% in the control group (

223 in mortality of 20 percentage points in the convalescent-plasma group as compared with the control g

224 At baseline, the convalescent-plasma group had slightly higher cycle-thre

225 In addition, Western blotting with convalescent rabbit serum detected cell wall proteins ex

226 munoblotting with monospecific antiserum and convalescent rat serum in addition to mass spectrometry.

227 gnificant increases between prechallenge and convalescent reactive IgG for all five GI VLPs measured

228 for peripheral blood taken from infected and convalescent recovering patients to identify early stage

229 eased in acute patients compared with paired convalescent samples (2.85 +/- 0.10 g/L and 74.4 +/- 2.5

230 ring anaphylaxis (median, 658 pg/mL) than in convalescent samples (314 and 311 pg/mL at 7 and 30 days

231 (</=3 weeks after stroke/trauma); cases had convalescent samples (7-28 days later) when feasible.

232 fferent in acute (81.4% +/- 1.7%) and paired convalescent samples (85.6% +/- 2.5%; p =.54).

233 hylaxis was also significantly lower than in convalescent samples (P </= .002) and control subjects w

234 (ie, during the anaphylactic episode and in convalescent samples 7 and 30 days later).

235 to determine T cell responses from 128 SARS convalescent samples by ex vivo IFN-gamma ELISPOT assays

236 Paired convalescent samples taken 8-10 wks after discharge were

237 Paired acute and convalescent samples were compared.

238 Approximately 50% of convalescent SARS patients were positive for T cell resp

239 The findings suggest that convalescent sera alone is not sufficient for providing

240 ape variants from human viruses treated with convalescent sera and from mice that had been previously

241 Convalescent sera and sera from other streptococcal dise

242 acaques treated with homologous ZEBOV-Makona convalescent sera died on days 8-9.

243 Convalescent sera from 20 cholera patients infected with

244 ps the site IV sequence reacted with all the convalescent sera from 42 SARS patient, but none of the

245 onses, were assessed by Luminex in acute and convalescent sera from 91 EM patients, in serum and syno

246 Convalescent sera from cholera patients had a mean vibri

247 t the recombinant E. canis p120 reacted with convalescent sera from dogs with canine ehrlichiosis.

248 e-linked immunosorbent assays of antibody in convalescent sera from mares naturally infected with L.

249 closely related viruses, we tested acute and convalescent sera from nine Thai patients with PCR-confi

250 ng the entire S protein sequence against the convalescent sera from SARS patients and antisera from s

251 by screening the genomic library with swine convalescent sera showing that P102 is expressed in vivo

252 One macaque treated with heterologous SEBOV convalescent sera survived, while the other animals trea

253 by incubating them with human and/or ferret convalescent sera to human H1N1 and H3N2 viruses.

254 The major antigens recognized by murine convalescent sera were F1, V antigen, YopH, YopM, YopD,

255 titers increased by >/=4-fold in those with convalescent sera.

256 potential of anti-GlcCer antibodies found in convalescent sera.

257 munoglobulin G antibodies to OMP B1 in their convalescent sera.

258 logy was nonreactive in all patients, though convalescent serology was reactive in 6 of 8 (75%) patie

259 Convalescent serum and blood were used to treat patients

260 fluenza virus IgG titer 2.5 times the normal convalescent serum anti-influenza virus IgG titer was re

261 We correlated acute and convalescent serum antibody levels with incidence of rec

262 The development of an antibody response in convalescent serum can temporarily link symptoms with a

263 he library was screened immunologically with convalescent serum from a child naturally infected with

264 ative Bsa-secreted proteins were detected in convalescent serum from a melioidosis patient, suggestin

265 or envelope protein 2-specific antibodies or convalescent serum from a recovered HCV patient or by an

266 Antibodies present in convalescent serum from C. jejuni-infected individuals a

267 ty (TNA) levels were determined in acute and convalescent serum of 26 case patients with suspected cu

268 ered in amounts designed to replicate murine convalescent serum or nasal Ab titers, respectively.

269 ologous equine antibodies and human anti-HGE convalescent serum recognized E. equi grown in tick cell

270 Paired acute and convalescent serum samples from children with GAS-associ

271 The convalescent serum samples of two vaccinees showed antib

272 Convalescent serum samples were examined for the ability

273 adults and 32.3% of children) who submitted convalescent serum specimens for antibody testing, respi

274 PCR) for Ehrlichia chaffeensis, 2) acute and convalescent serum titers, and 3) in vitro cultivation o

275 Passive immunization with immune (convalescent) serum conferred a marked level of protecti

276 Patients who retain the convalescent signature may be genetically or temporarily

277 Most (78%) had seropositive convalescent specimens.

278 tection of seroconversion between acute- and convalescent-stage samples.

279 for anti-F IgG in 1,380 pairs of acute- and convalescent-stage serum samples collected from children

280 erum samples from patients in both acute and convalescent stages of illness were analyzed for changes

281 The presence of IFA during both acute and convalescent stages of infection, as well as significant

282 ifferentially abundant between the acute and convalescent stages of infection; the majority of these

283 roRNAs from whole blood during the acute and convalescent stages of the illness.

284 m the early febrile to the defervescence and convalescent stages of the infection.

285 ermal Texture Index scores in both acute and convalescent states (respective r = -0.80 and -0.75, P <

286 AD in relation to FLG genotype and acute and convalescent status.

287 Acute and convalescent stool, serum, and saliva samples from cases

288 he CHO assay were similar for vaccinated and convalescent subjects; however, the convalescent group h

289 ATCC 49776) genomic DNA with hyperimmune and convalescent swine sera.

290 Convalescent testing was not performed for 37 (86%) of t

291 or equivocal results; 24 (26%) of the 93 had convalescent testing, with 1 seroconversion.

292 ia were reported significantly more often by convalescents than HHCs.

293 memory B cells (CD38(-)CD27(+)) at the early convalescent time point.

294 From these convalescent time points, we identified CD4 and CD8 T-ce

295 ainst Hla and LukF but displayed the highest convalescent titers.

296 No direct evidence of convalescent-to-HHC transmission of EHF was found, altho

297 timates for EVD in Liberia and assuming that convalescent transfusions reduce the case-fatality rate

298 h Organization urged the rapid evaluation of convalescent whole blood (CWB) and plasma (CP) transfusi

299 -/-) mice was not as effective as serum from convalescent wild-type mice in clearing this pathogen fr

300 mphocytes, and purified B1b lymphocytes from convalescent wild-type or TCR-betaxdelta-/- mice conferr